ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Molecular Epidemiology of Childhood Leukemia in Northern and Central California

This study is currently recruiting participants.
Verified by National Institute of Environmental Health Sciences (NIEHS), November 2000

Sponsors and Collaborators: National Institute of Environmental Health Sciences (NIEHS)
National Cancer Institute (NCI)
Information provided by: National Institute of Environmental Health Sciences (NIEHS)
ClinicalTrials.gov Identifier: NCT00015587
  Purpose

This study is a case-control study investigating the causes of childhood leukemia in Northern California. The overall purpose of this epidemiologic study is to find specific genetic or environmental factors that may increase the risk of leukemia in children. The study is being conducted by Patricia Buffler, PhD at the School of Public Health, the University of California Berkeley, with collaboration by the California Department of Health Services and nine other Bay Area and Central Valley hospitals. The study began in 1995 and will continue to 2003.


Condition
Leukemia
Acute Myelocytic Leukemia
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia

MedlinePlus related topics:   Leukemia, Childhood   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Case Control, Prospective Study
Official Title:   Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure

Further study details as provided by National Institute of Environmental Health Sciences (NIEHS):

Estimated Enrollment:   1200
Study Start Date:   April 1995
Estimated Study Completion Date:   March 2005

Detailed Description:

This study is a case-control study of incident childhood leukemia (all subtypes) diagnosed since mid-1995. Children newly diagnosed with leukemia are enrolled in the study. Criteria for inclusion in the study are: under 15 years of age, no prior cancer diagnosis, residency in one of 35 counties at the time of diagnosis, and availability of an English or Spanish speaking parent or guardian. Pre-treatment biological specimens including bone marrow and peripheral blood are obtained for analysis in the UCB lab of Dr. M. Smith. He will use Fluorescence In Situ Hybridization (FISH) to detect chromosome specific aneuploidy and translocations. A number of chromosomal translocations, including t(9;22) and t(8;21), are known to be centrally involved in the development of childhood leukemia. Molecular characterization of the cases with translocations may provide insight into the timing of critical exposures and the nature of the etiological agent involved.

Two comparison subjects (controls) are recruited for each consenting case. For each case, four potential controls are randomly selected from California birth certificate files and matched on date of birth, gender, mother's race, parental Hispanicity, and county of residence. One of the four birth certificate controls is randomly selected to be recruited to participate in the study.

An in-depth personal interview asks a variety of questions, including: residential history; occupational and household exposure histories; dietary history of child until the age of three and biological mother at the time of conception and during pregnancy; mothers' reproductive history; events during index pregnancy and delivery; family history of illness; child's health and vaccination history, contact with other children, and location of schools; maternal and child exposure to cigarette smoke during pregnancy and since birth; maternal and child history of x-rays; and hobby and craft exposures during pregnancy until age three.

Buccal cell specimens are obtained from the cases and controls and their biological mothers. The buccal cells are sent to Dr. J. Wiencke's Lab of Molecular Epidemiology at UCSF. DNA from cases and controls will be analyzed by polymerase chain reaction for genetic polymorphisms. Genetic polymorphisms will be examined in two glutathione transferase genes, M1 and Tl. Case samples of peripheral blood, bone marrow, and archived newborn blood will be also used to detect N-ras mutation.

Three tiers of an exposure assessment are being implemented. Tier 1 enrolls and interviews cases and controls seeking to identify risk factors, including residential and occupational chemical exposures. In Tier 2, cases and birth certificate controls that have not changed residence based on specific criteria are part of a reliability study, which seeks to determine if self-reported chemicals used at the time of interview are found in the home during a visual survey several months after interview. Tier 3 aims to document the potential for household exposures by sampling dust on the floor surfaces. The objective is to identify if there are differences in concentrations of pesticides, metals, polyaromatic hydrocarbons, cotinine, polychorinated biphenyls, and ethylenethiourea in the homes of cases and controls. Further, a case-case analysis will identify if cases with chromosomal translocations of interest live in homes with higher concentrations of target compounds than cases that do not have such translocations. These analyses will determine whether leukemic children with common genetic changes experience common exposures and whether these genetic changes have approximately the same temporal occurrence. Finally, we will evaluate whether children with and without leukemia differ with respect to susceptibility.

  Eligibility
Ages Eligible for Study:   up to 14 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Cases must be children ages 0-14 newly diagnosed with leukemia (any type) at one of participating hospitals. They must live in one of 35 No. California counties, never have been diagnosed with a prior cancer and have a parent or guardian that speaks English or Spanish.

Controls are matched on the case child's DOB, gender, mother's race, parent's Hispanicity. In order to be eligible, they must have no history of cancer, have a parent or guardian that speaks English or Spanish and they must live in one of 35 No. California counties.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00015587

Contacts
Contact: Monique B Does, Project Manager     510-643-8399     mobuff@uclink.berkeley.edu    

Locations
United States, California
University of California, School of Public Health, Childhood Leukemia Study     Recruiting
      Berkeley, California, United States, 94720-7380
      Contact: Karen Pfister, MPH     510-642-6167     kpfister@uclink.berkeley.edu    
      Contact: Monique B Does     510-643-8399     mobuff@uclink4.berkeley.edu    
      Principal Investigator: Patricia A Buffler, PhD, MPH            
California Dept. of Health Services, Environmental Health Investigations Branch     Recruiting
      Oakland, California, United States, 94612
      Contact: Peggy Reynolds, PhD     510-622-4417     preynold@dhs.ca.gov    
      Sub-Investigator: Peggy Reynolds, PhD            
Children's Hospital Oakland, Pediatric Oncology/Hematology     Recruiting
      Oakland, California, United States, 94609
      Contact: Jim Fuesner, MD     510-428-3689     cho.dr.jhf@cho.org    
      Sub-Investigator: Jim Fuesner, MD            

Sponsors and Collaborators

Investigators
Principal Investigator:     Patricia A Buffler, PhD     University of California Berkeley, School of Public Health    
  More Information


Study ID Numbers:   9137-CP-001
First Received:   April 23, 2001
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00015587
Health Authority:   United States: Federal Government

Keywords provided by National Institute of Environmental Health Sciences (NIEHS):
Molecular Epidemiology  
Case Control  

Study placed in the following topic categories:
Lymphatic Diseases
Leukemia
Leukemia, Lymphoid
Immunoproliferative Disorders
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute myelogenous leukemia
Leukemia, Myeloid
Lymphoproliferative Disorders
Leukemia, Myeloid, Acute
Acute myelocytic leukemia
Lymphoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers